• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于健康体检指标在识别代谢功能障碍相关脂肪性肝病中的效用。

Usefulness of health checkup-based indices in identifying metabolic dysfunction-associated steatotic liver disease.

作者信息

Miwa Takao, Tajirika Satoko, Imamura Nanako, Adachi Miho, Horita Ryo, Hanai Tatsunori, Ng Cheng Han, Siddiqui Mohammad Shadab, Fukao Taku, Shimizu Masahito, Yamamoto Mayumi

机构信息

Health Administration Center Gifu University Gifu Japan.

Department of Gastroenterology/Internal Medicine, Graduate School of Medicine Gifu University Gifu Japan.

出版信息

JGH Open. 2024 Jun 17;8(6):e13110. doi: 10.1002/jgh3.13110. eCollection 2024 Jun.

DOI:10.1002/jgh3.13110
PMID:38895100
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11183927/
Abstract

AIMS

The application of indices in the context of metabolic dysfunction-associated steatotic liver disease (MASLD) remains unexplored. We aimed to validate the ability of alanine aminotransferase (ALT), fatty liver index (FLI), and hepatic steatosis index (HSI) to identify MASLD during health checkups.

METHODS

We recruited 627 participants and utilized their health checkup data and ultrasound to assess the potential of using ALT, FLI, and HSI as indices for MASLD; this was indicated by the area under the curve (AUC) and restricted cubic spline (RCS) model. The optimal, rule-out (sensitivity ≥90%), and rule-in (specificity ≥90%) cutoff values of each index for identifying MASLD were reported.

RESULTS

Among participants with a median age of 46 years, the prevalence of MASLD was 28% in total (38% in males and 18% in females). RCS models confirmed a linear association between indices and MASLD. ROC analyses indicated that the AUC of ALT in identifying MASLD was 0.79 for the total cohort, 0.81 for males, and 0.69 for females. The optimal, rule-out, and rule-in cutoff values for ALT were 21, 13, and 29, respectively. Similarly, the AUC of FLI/HSI in identifying MASLD was 0.90/0.88 for the total cohort, 0.86/0.85 for males, and 0.93/0.90 for females. Considering the reference cutoff values, distinct cutoff values were observed between the sexes for FLI, while HSI had similar cutoff values.

CONCLUSION

This study demonstrated that ALT > 30 IU/L is a reasonable cutoff value to rule-in MASLD. ALT, FLI, and HSI are reliable indices for identifying MASLD during health checkups.

摘要

目的

代谢功能障碍相关脂肪性肝病(MASLD)背景下各项指标的应用仍未得到充分研究。我们旨在验证丙氨酸氨基转移酶(ALT)、脂肪肝指数(FLI)和肝脂肪变指数(HSI)在健康体检中识别MASLD的能力。

方法

我们招募了627名参与者,并利用他们的健康体检数据和超声来评估使用ALT、FLI和HSI作为MASLD指标的潜力;这通过曲线下面积(AUC)和限制立方样条(RCS)模型来表示。报告了各指标识别MASLD的最佳、排除(敏感性≥90%)和纳入(特异性≥90%)临界值。

结果

在中位年龄为46岁的参与者中,MASLD的总体患病率为28%(男性为38%,女性为18%)。RCS模型证实了各项指标与MASLD之间存在线性关联。ROC分析表明,ALT识别MASLD的AUC在总队列中为0.79,男性为0.81,女性为0.69。ALT的最佳、排除和纳入临界值分别为21、13和29。同样,FLI/HSI识别MASLD的AUC在总队列中为0.90/0.88,男性为0.86/0.85,女性为0.93/0.90。考虑到参考临界值,FLI在性别之间观察到不同的临界值,而HSI的临界值相似。

结论

本研究表明,ALT>30 IU/L是纳入MASLD的合理临界值。ALT、FLI和HSI是健康体检中识别MASLD的可靠指标。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c54/11183927/cfa45373e43b/JGH3-8-e13110-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c54/11183927/708ab6e522a4/JGH3-8-e13110-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c54/11183927/69ccd24c25b4/JGH3-8-e13110-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c54/11183927/b764e00390b2/JGH3-8-e13110-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c54/11183927/cfa45373e43b/JGH3-8-e13110-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c54/11183927/708ab6e522a4/JGH3-8-e13110-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c54/11183927/69ccd24c25b4/JGH3-8-e13110-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c54/11183927/b764e00390b2/JGH3-8-e13110-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c54/11183927/cfa45373e43b/JGH3-8-e13110-g005.jpg

相似文献

1
Usefulness of health checkup-based indices in identifying metabolic dysfunction-associated steatotic liver disease.基于健康体检指标在识别代谢功能障碍相关脂肪性肝病中的效用。
JGH Open. 2024 Jun 17;8(6):e13110. doi: 10.1002/jgh3.13110. eCollection 2024 Jun.
2
Fatty Liver Index (FLI) is the best score to predict MASLD with 50% lower cut-off value in women than in men.脂肪肝指数(FLI)是预测 MASLD 的最佳评分,女性的截断值比男性低 50%。
Biol Sex Differ. 2024 May 17;15(1):43. doi: 10.1186/s13293-024-00617-z.
3
Associations between serum ferritin baselines and trajectories and the incidence of metabolic dysfunction-associated steatotic liver disease: a prospective cohort study.血清铁蛋白基线和轨迹与代谢功能障碍相关脂肪性肝病发病的关系:一项前瞻性队列研究。
Lipids Health Dis. 2024 May 17;23(1):141. doi: 10.1186/s12944-024-02129-6.
4
Correlation Between Metabolic Dysfunction-Associated Steatotic Liver Disease and the Risk of Urinary Incontinence in Adult Women.代谢功能障碍相关脂肪性肝病与成年女性尿失禁风险之间的相关性
Int J Womens Health. 2024 Sep 30;16:1607-1624. doi: 10.2147/IJWH.S489959. eCollection 2024.
5
Noninvasive Indices of MASLD Are Associated With Hypogonadism in Male Patients With Type 2 Diabetes Mellitus.非侵入性 MASLD 指数与 2 型糖尿病男性患者的性腺功能减退症相关。
J Clin Endocrinol Metab. 2024 Jan 18;109(2):e522-e530. doi: 10.1210/clinem/dgad586.
6
Blood glucose control and metabolic dysfunction-associated steatotic liver disease in people with type 1 diabetes.1 型糖尿病患者的血糖控制与代谢功能障碍相关的脂肪性肝病。
J Endocrinol Invest. 2024 Sep;47(9):2371-2378. doi: 10.1007/s40618-024-02333-2. Epub 2024 Mar 18.
7
Non-invasive assessment of hepatic steatosis by ultrasound-derived fat fraction in individuals at high-risk for metabolic dysfunction-associated steatotic liver disease.应用超声弹性成像技术检测代谢相关脂肪性肝病高危人群肝脏脂肪分数的非侵入性评估。
Diabetes Metab Res Rev. 2024 Mar;40(3):e3787. doi: 10.1002/dmrr.3787.
8
Assessment of the clinical value of five noninvasive predictors of metabolic dysfunction-associated steatotic liver disease in Han Chinese adults.评估五种非侵入性预测因子在汉族成年人代谢相关脂肪性肝病中的临床价值。
Eur J Gastroenterol Hepatol. 2024 Oct 1;36(10):1209-1219. doi: 10.1097/MEG.0000000000002806. Epub 2024 Jun 26.
9
Bioelectrical impedance parameters add incremental value to waist-to-hip ratio for prediction of metabolic dysfunction associated steatotic liver disease in youth with overweight and obesity.生物电阻抗参数为预测超重和肥胖青少年与代谢功能障碍相关的脂肪性肝病增加了腰臀比的附加值。
Front Endocrinol (Lausanne). 2024 May 31;15:1385002. doi: 10.3389/fendo.2024.1385002. eCollection 2024.
10
ALT levels, alcohol use, and metabolic risk factors have prognostic relevance for liver-related outcomes in the general population.谷丙转氨酶(ALT)水平、饮酒情况和代谢风险因素对普通人群的肝脏相关结局具有预后相关性。
JHEP Rep. 2024 Jul 24;6(10):101172. doi: 10.1016/j.jhepr.2024.101172. eCollection 2024 Oct.

引用本文的文献

1
Comparative evaluation of FIB-3 and FIB-4 indices for liver fibrosis screening in workplace-based health checkups.在基于工作场所的健康检查中用于肝纤维化筛查的FIB-3和FIB-4指标的比较评估
J Occup Health. 2025 Jan 7;67(1). doi: 10.1093/joccuh/uiaf038.
2
Metabolic outcomes in non-alcoholic and alcoholic steatotic liver disease among Korean and American adults.韩国和美国成年人中非酒精性和酒精性脂肪性肝病的代谢结果。
BMC Gastroenterol. 2025 Feb 24;25(1):110. doi: 10.1186/s12876-025-03687-4.
3
The Effects of Oral Semaglutide on Hepatic Fibrosis in Subjects with Type 2 Diabetes in Real-World Clinical Practice: A Post Hoc Analysis of the Sapporo-Oral SEMA Study.

本文引用的文献

1
Deciphering metabolic dysfunction-associated steatotic liver disease: insights from predictive modeling and clustering analysis.解析代谢相关脂肪性肝病:预测模型和聚类分析的新视角。
J Gastroenterol Hepatol. 2024 Jul;39(7):1382-1393. doi: 10.1111/jgh.16552. Epub 2024 Apr 17.
2
Changing from NAFLD to MASLD: Prevalence and progression of ASCVD risk are similar between NAFLD and MASLD in Asia.从非酒精性脂肪性肝病(NAFLD)转变为代谢功能障碍相关脂肪性肝病(MASLD):在亚洲,NAFLD和MASLD之间动脉粥样硬化性心血管疾病(ASCVD)风险的患病率和进展情况相似。
Clin Mol Hepatol. 2024 Jul;30(3):577-579. doi: 10.3350/cmh.2024.0157. Epub 2024 Mar 6.
3
口服司美格鲁肽对2型糖尿病患者在真实世界临床实践中肝纤维化的影响:札幌口服司美格鲁肽研究的事后分析
Pharmaceuticals (Basel). 2025 Jan 19;18(1):129. doi: 10.3390/ph18010129.
4
Association between metabolic dysfunction associated steatotic liver disease and gallstones in the US population using propensity score matching.使用倾向评分匹配法分析美国人群中代谢功能障碍相关脂肪性肝病与胆结石之间的关联。
Sci Rep. 2025 Jan 6;15(1):910. doi: 10.1038/s41598-025-85218-5.
Changing from NAFLD to MASLD: The implications for health-related quality of life data.
从非酒精性脂肪性肝病转变为代谢功能障碍相关脂肪性肝病:对健康相关生活质量数据的影响。
J Hepatol. 2024 Jun;80(6):e249-e251. doi: 10.1016/j.jhep.2024.02.010. Epub 2024 Feb 23.
4
Prevalence of Steatotic Liver Disease Based on a New Nomenclature in the Japanese Population: A Health Checkup-Based Cross-Sectional Study.基于新命名法的日本人群脂肪性肝病患病率:一项基于健康体检的横断面研究。
J Clin Med. 2024 Feb 19;13(4):1158. doi: 10.3390/jcm13041158.
5
Profiles associated with significant hepatic fibrosis consisting of alanine aminotransferase >30 U/L, exercise habits, and metabolic dysfunction-associated steatotic liver disease.与显著肝纤维化相关的特征包括丙氨酸氨基转移酶>30 U/L、运动习惯以及代谢功能障碍相关脂肪性肝病。
Hepatol Res. 2024 Jul;54(7):655-666. doi: 10.1111/hepr.14020. Epub 2024 Jan 31.
6
Usefulness of a questionnaire for assessing the relationship between eating behavior and steatotic liver disease among Japanese male young adults.一份用于评估日本年轻男性饮食行为与脂肪性肝病之间关系的问卷的效用。
Sci Rep. 2024 Jan 25;14(1):2194. doi: 10.1038/s41598-024-52797-8.
7
Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study.经活检证实的代谢相关脂肪性肝病的预后:CLIONE 研究的亚分析。
Clin Mol Hepatol. 2024 Apr;30(2):225-234. doi: 10.3350/cmh.2023.0515. Epub 2024 Jan 24.
8
Changing from NAFLD to MASLD: Similar prognosis of patients with HCC under atezolizumab/bevacizumab treatment between NAFLD and MASLD.从非酒精性脂肪性肝病转变为代谢相关脂肪性肝病:在阿替利珠单抗/贝伐单抗治疗下,非酒精性脂肪性肝病和代谢相关脂肪性肝病患者发生肝细胞癌的预后相似。
Clin Mol Hepatol. 2024 Apr;30(2):263-265. doi: 10.3350/cmh.2023.0557. Epub 2024 Jan 18.
9
Concordance between metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease.代谢功能障碍相关脂肪性肝病与非酒精性脂肪性肝病之间的一致性
Hepatol Res. 2024 Jun;54(6):600-605. doi: 10.1111/hepr.14011. Epub 2024 Jan 17.
10
Almost identical values of various non-invasive indexes for hepatic fibrosis and steatosis between NAFLD and MASLD in Asia.在亚洲,非酒精性脂肪性肝病(NAFLD)和代谢相关脂肪性肝病(MASLD)之间,用于评估肝纤维化和脂肪变性的各种非侵入性指标的值几乎相同。
J Hepatol. 2024 Apr;80(4):e155-e157. doi: 10.1016/j.jhep.2023.12.030. Epub 2024 Jan 13.